Invasive aspergillosis among heart transplant recipients is rare but causes rapid death due to septic shock and multiple organ dysfunction syndrome

Scandinavian Journal of Infectious Diseases

Volumn 44, Issue 12, 2012, Pages 982-986

  Shields, Ryan K ^a   Nguyen, M Hong ^a   Shullo, Michael A ^b   Silveira, Fernanda P ^a   Kwak, Eun J ^a   Abdel Massih, Rima C ^a   Toyoda, Yoshiya ^a   Bermudez, Christian A ^a   Bhama, Jay K ^a   Kormos, Robert L ^a   Clancy, Cornelius J ^a,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Aspergillosis; Heart transplant; Septic shock

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; ITRACONAZOLE; VORICONAZOLE;

ADULT; AGED; ANTIMICROBIAL THERAPY; ARTICLE; DISEASE ASSOCIATION; FEMALE; GRAFT RECIPIENT; HEART TRANSPLANTATION; HUMAN; INVASIVE ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE ORGAN FAILURE; RISK FACTOR; SEPTIC SHOCK;

ADULT; AGED; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; INVASIVE PULMONARY ASPERGILLOSIS; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; RISK FACTORS; SHOCK, SEPTIC; SURVIVAL ANALYSIS; TRANSPLANTATION;

EID: 84874124243     PISSN: 00365548     EISSN: 16511980     Source Type: Journal    
DOI: 10.3109/00365548.2012.705018     Document Type: Article

References (21)

1. Singh N, Husain S. I nvasive aspergillosis in solid organ transplant recipients. Am J Transplant 2009; 9(Suppl 4): S180-91.
2. Munoz P, Rodriguez C, Bouza E, Palomo J, Yanez JF, Dominguez MJ, et al. Risk factors of invasive aspergillosis after heart transplantation: Protective role of oral itraconazole prophylaxis. Am J Transplant 2004; 4: 636-43.
3. Marty FM, Koo S. R ole of (1 - 3)-beta-d-glucan in the diagnosis of invasive aspergillosis. Med Mycol 2009; 47(Suppl 1): S233-40.
4. Luong ML, Clancy CJ, Vadnerkar A, Kwak EJ, Silveira FP, Wissel MC, et al. Comparison of a commercial Aspergillus real-time PCR assay with galactomannan testing of BAL fluid for the diagnosis of invasive pulmonary aspergillosis in lung transplant recipients. Clin Infect Dis 2011; 52: 1218-26.
5. Maertens J, Van Eldere J, Verhaegen J, Verbeken E, Verschakelen J, Boogaerts M. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis 2002; 186: 1297-306.
6. Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 2010; 50: 1101-11.
7. Montoya JG, Chaparro SV, Celis D, Cortes JA, Leung A N, Robbins RC, et al. Invasive aspergillosis in the setting of cardiac transplantation. Clin Infect Dis 2003; 37(Suppl 3): S281-92.
8. Grossi P, Farina C, Fiocchi R, Dalla Gasperina D. P revalence and outcome of invasive fungal infections in 1,963 thoracic organ transplant recipients: A multicenter retrospective study. Italian Study Group of Fungal Infections in Thoracic Organ Transplant Recipients. Transplantation 2000; 70: 112-6.
9. Utili R, Zampino R, D e Vivo F, Maiello C, Andreana A, Mormone G, et al. Improved outcome of pulmonary aspergillosis in heart transplant recipients with early diagnosis and itraconazole treatment. Clin Transplant 2000; 14(4 Pt 1): 282-6.
10. Paniagua Martin MJ, Marzoa Rivas R, Barge Caballero E, Grille Cancela Z, Fernandez CJ, Solla M, et al. Effi cacy and tolerance of different types of prophylaxis for prevention of early aspergillosis after heart transplantation. Transplant Proc 2010; 42: 3014-6.
11. Teuteberg J J, Shullo M, Zomak R, McNamara D, McCurry K, Kormos RL. Aggressive steroid weaning after cardiac transplantation is possible without the additional risk of signifi cant rejection. Clin Transplant 2008; 22: 730-7.
12. De Pauw B, Walsh T J, Donnelly JP, Stevens DA, Edwards JE, Calandra T, et al. Revised defi nitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
13. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36: 296-327.
14. Chou NK, Chi NH, W u IW, Huang SC, Chen YS, Y u HY, et al. Fungal infection in heart transplant recipients with severe sepsis: Single-center experience. Transplant Proc 2010; 42: 952-4.
15. Munoz P, Alcala L, Sanchez Conde M, Palomo J, Yanez J, Pelaez T, et al. The isolation of Aspergillus fumigatus from respiratory tract specimens in heart transplant recipients is highly predictive of invasive aspergillosis. Transplantation 2003; 75: 326-9.
16. Gurwith MJ, Stinson EB, Remington JS. A spergillus infection complicating cardiac transplantation. Report of fi ve cases. Arch Intern Med 1971; 128: 541-5.
17. Montoya J G, Giraldo L F, Efron B, Stinson E B, Gamberg P, Hunt S, et al. Infectious complications among 620 consecutive heart transplant patients at Stanford University Medical Center. Clin Infect Dis 2001; 33: 629-40.
18. Baddley J W, Andes D R, Marr K A, Kontoyiannis D P, Alexander BD, Kauffman CA, et al. Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis 2010; 50: 1559-67.
19. Kox WJ, Volk T, Kox SN, Volk HD. I mmunomodulatory therapies in sepsis. Intensive Care Med 2000; 26(Suppl 1): S124-8.
20. Clancy CJ, Jaber RA, Leather HL, Wingard JR, Staley B, Wheat LJ, et al. Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J Clin Microbiol 2007; 45: 1759-65.
21. Nucci M, Nouer SA, Grazziutti M, Kumar N S, Barlogie B, Anaissie E. Probable invasive aspergillosis without prespecifi ed radiologic fi ndings: Proposal for inclusion of a new category of aspergillosis and implications for studying novel therapies. Clin Infect Dis 2010; 51: 1273-80.